CytomX Therapeutics (CTMX) Earnings Analysis

CytomX Therapeutics (CTMX) next reports earnings on 2026-08-06, consensus EPS -0.11 USD. Last quarter (2026-05-07) it beat with EPS -0.1 USD vs -0.14 USD est (+28.6%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -9.22.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CTMX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.11 USD
Revenue estimate0.01B

CTMX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.1 USD-0.14 USD+28.6%Beat
2026-03-16-0.22 USD-0.08 USD-175%Miss
2025-05-120.27 USD0.1248 USD+116.3%Beat
2025-03-060.22 USD-0.23 USD+195.7%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

CTMX valuation and analyst view

Trailing P/E-9.22
Trailing EPS-0.33362 USD
Price / book1.85
Dividend yield0.00%
Market cap0.54B
Analyst consensusBuy (17 buy / 4 hold / 0 sell)
Avg price target8.5 USD

Related research pages

Frequently asked questions

When is CytomX Therapeutics (CTMX)'s next earnings date?

CytomX Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.11 USD and revenue estimate of 0.01B.

Did CTMX beat earnings last quarter?

In its 2026-05-07 report, CTMX posted EPS of -0.1 USD versus a -0.14 USD estimate — a beat of 28.6%.

What is CTMX's earnings track record?

Over the last 4 reported quarters with consensus data, CTMX beat estimates 3 times (75%).

What is CTMX's current P/E ratio and EPS?

CTMX trades at a trailing P/E of -9.22 on trailing EPS of -0.33361538418146025 USD.

What do analysts rate CTMX?

Analyst consensus is "Buy" across 21 ratings (0 strong buy, 17 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 8.5 USD.